PCF11-AS1: A Non-Coding RNA Molecule as a Potential Drug Target or Biomarker

Target Name: PCF11-AS1

NCBI ID: G106736475

PCF11-AS1

Other Name(s): PCF11 antisense RNA 1

PCF11-AS1: A Non-Coding RNA Molecule as a Potential Drug Target or Biomarker

PCF11-AS1, also known as PCF11-AS1 RNA, is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. PCF11-AS1 is derived from the polycombine repeat gene (PCG) family, which is known for the formation of repetitive RNA structures. This gene has been shown to be involved in various cellular processes, including cell growth, differentiation, and RNA homeostasis.

The discovery of PCF11-AS1

The PCF11-AS1 gene was first identified in the genomic database using a combination of bioinformatic tools, such as DNA sequencing and RNA sequencing. The PCF11-AS1 gene was found to be located on chromosome 16, at position 11.35馃槈.

Expression of PCF11-AS1

PCF11-AS1 is a highly expressed gene in various tissues, including brain, heart, liver, and muscle. It has been shown to be expressed in a variety of cell types, including epithelial, muscle, and neural cells. PCF11-AS1 has also been shown to be expressed in various biological processes, including cell growth, differentiation, and cell cycle regulation.

Function of PCF11-AS1

PCF11-AS1 is involved in the regulation of various cellular processes, including cell growth, differentiation, and RNA homeostasis. It has been shown to play a role in cell cycle regulation, specifically in G1 phase and G2 phase of the cell cycle.

PCF11-AS1 has also been shown to be involved in the regulation of gene expression. It has been shown to interact with various proteins, including the transcription factor, p53. This interaction between PCF11-AS1 and p53 suggests that PCF11-AS1 may play a role in the regulation of cellular processes, including cell growth and differentiation.

Drug targeting PCF11-AS1

The potential drug targeting of PCF11-AS1 is based on its involvement in various cellular processes, including cell growth, differentiation, and RNA homeostasis. Drugs that have been shown to target PCF11-AS1 include inhibitors of the translation of PCF11-AS1 RNA, as well as antibodies that specifically bind to PCF11-AS1.

One such drug that has been shown to target PCF11-AS1 is Nutlin-3A, which is a small molecule inhibitor of PCF11-AS1 translation. Nutlin-3A has been shown to reduce the levels of PCF11-AS1 in various cell types, including cancer cells.

Another drug that has been shown to target PCF11-AS1 is monoclonal antibody 2A3, which is specific for PCF11-AS1. 2A3 has been shown to bind to PCF11-AS1 with high affinity and has been shown to inhibit the translation of PCF11-AS1 RNA in various cell types.

Conclusion

In conclusion, PCF11-AS1 is a non-coding RNA molecule that has been shown to be involved in various cellular processes, including cell growth, differentiation, and RNA homeostasis. Its potential as a drug target or biomarker is based on its involvement in these processes. Nutlin-3A and 2A3 are two examples of drugs that have been shown to target PCF11-AS1 and have been shown to inhibit its translation in various cell types. Further research is needed to fully understand the role of PCF11-AS1 in cellular processes and its potential as a drug target or biomarker.

Protein Name: PCF11 Antisense RNA 1

The "PCF11-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCF11-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets